What's in Joon Bum Kim's pipeline?

Joon Bum Kim has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Joon Bum Kim's portfolio?

Top competitors by shared drug class: Population Health Research Institute, US Department of Veterans Affairs, University Hospital, Bonn, University Hospital, Limoges, Yunhe Pharmaceutical (Tianjin) Co., Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/joon-bum-kim.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Joon Bum Kim — Portfolio Competitive Intelligence Brief

Joon Bum Kim pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Vitamin K antagonist(warfarin)	Vitamin K antagonist(warfarin)	marketed	Vitamin K antagonist	Vitamin K epoxide reductase (VKORC1)	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Population Health Research Institute · 1 shared drug class
US Department of Veterans Affairs · 1 shared drug class
University Hospital, Bonn · 1 shared drug class
University Hospital, Limoges · 1 shared drug class
Yunhe Pharmaceutical (Tianjin) Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Joon Bum Kim:

Cite this brief

Drug Landscape (2026). Joon Bum Kim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/joon-bum-kim. Accessed 2026-05-15.